New Jersey

New Jersey's pharmaceutical services manual lists, under "Non-covered pharmaceutical services," item 2: "Antiobesics and anorexiants, with the exception of lipase inhibitors, when used in treatment of obesity (see N.J.A.C. 10:51-1.14, Prior authorization); coverage of lipase inhibitors shall be limited to obese individuals with a Body Mass Index (BMI) equal to or greater than 27 kg/m2 and less than 30 kg/m2 with co-morbidities of hypertension, diabetes or dyslipidemia; and obese individuals with a BMI equal to or greater than 30 kg/m2 without comorbidities." The prior authorization section adds that anorexiants and antiobesics can be authorized "when used for the treatment of conditions approved by the New Jersey State Board of Medical Examiners at N.J.A.C. 13:35-6.7." The copy we read is the department's, current through the New Jersey Register of June 16, 2025.

New Jersey Department of Human Services, N.J.A.C. 10:51 (Pharmaceutical Services Manual), §10:51-1.13 and §10:51-1.14, effective June 2025 · source

Then the state studied it. The department's memo, titled NJ FamilyCare Coverage of Weight Loss Drugs, whose cost estimates it says were developed in August 2025, was written because "The SFY 2026 enacted New Jersey state budget included language directing" the department to examine "the viability and likely cost to the State of providing coverage for such drugs." Its answer on current policy: "Under existing federal and state law, NJ FamilyCare already provides coverage of drugs indicated for weight loss in certain limited circumstances. These include when drugs (including Glucagon-like peptide-1 agonists or GLP-1s) are prescribed for FDA-approved indications other than weight loss. For instance, Wegovy is covered when clinically appropriate for cardiovascular disease, and Zepbound is covered for sleep apnea." On extending it, the memo says federal cuts "starting in SFY27" are "creating budgetary challenges which may constrain the State's ability to extend full coverage for anti-obesity medications." The memo prints no date on its face.

New Jersey Department of Human Services, Division of Medical Assistance and Health Services, NJ FamilyCare Coverage of Weight Loss Drugs (memo to the Legislature) · source

The board that sets the state's drug protocols said it plainly. The summary of the Drug Utilization Review Board's October 22, 2025 meeting records, against a note on rising use of the GLP-1 class: "The Board noted these drugs are not covered for the diagnosis of obesity alone."

New Jersey Department of Human Services, Drug Utilization Review Board, October 22, 2025 Meeting Summary, effective October 2025 · source

The transcript of the board's July 16, 2025 meeting has a state pharmacy staff member answering a board member's question about these drugs: "So, Medicaid does not cover it just for obesity. But Zepbound, which is indicated for OSA, for people who are obese, is covered, and we have a separate protocol for that." We could not find that protocol published: the board's approved-protocols page links three documents, none for Zepbound or Wegovy, and six guessed filenames on the same host returned 404.

New Jersey Department of Human Services, Drug Utilization Review Board, July 16, 2025 Meeting Transcript, effective July 2025 · source

What your plan may do with its list, from the state's managed care contract. "Use of Formulary. The Contractor may use a formulary as long as the general requirements and the following minimum requirements are met: 1. The Contractor shall only exclude coverage of drugs or drug categories permitted under Section 1927(d) of the Social Security Act," and "The formulary for the DMAHS pharmacy benefit and any revision thereto shall be reviewed and approved by DMAHS prior to implementation." The same contract sets the plan-level appeal windows: "The Contractor must provide enrollees 60 days to file appeals from the date of the Contractor's notice of action letter. In the case of a Fair Hearing, the enrollee must file a request within 120 days of the date of the notice of action letter following an adverse determination resulting from an internal appeal," and the plan's notice must tell you that you "must complete the internal appeal process prior to the initiation of the Fair Hearing process." The contract edition we read is marked accepted January 2026.

New Jersey Department of Human Services, Division of Medical Assistance and Health Services, NJ FamilyCare Managed Care Contract, effective January 2026 · source

The fair hearing clock was reset on July 1, 2026. Medicaid Communication 26-06, dated June 23, 2026, says: "Per N.J.A.C. § 10:49-10.3(b), claimants have 20 days from the date of receipt of the notice of action to request a fair hearing. However, in 2023, DMAHS instituted a temporary 60-day filing period," which it is ending. It then explains how the 20 days are counted from a mailed notice: "the 20-day clock will begin 10 days after the date on the notice," so "Fair Hearing Notices will explain that beneficiaries have 30 days to request a fair hearing from the date on the notice. The request must be made within 30 days of the date on the notice, with either proof of mailing or faxing within that 30-day period." The same communication says that from July 1, 2026 "continuation of benefits while a fair hearing is pending will no longer automatically be granted" and that notices will require you to "affirmatively elect continuation of benefits."

New Jersey Department of Human Services, Division of Medical Assistance and Health Services, Medicaid Communication No. 26-06 (Operational Changes to Medicaid Fair Hearing Process), effective July 2026 · source